GLYC - GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

GlycoMimetics (GLYC) announces that the first patient has been dosed in an investigator-sponsored trial ((IST)) evaluating uproleselan as a prophylactic agent to reduce gastrointestinal ((GI)) toxicities associated with cell transplantation for multiple myeloma ((MM)).The trial aims to study the GI toxicities associated with high-dose melphalan in autologous hematopoietic cell transplantation (auto-HCT) for the condition.The study led by Washington University is a Phase 2, single-center, randomized, double-blind, and placebo-controlled IST designed to evaluate whether prophylactic uproleselan plus standard of care ((SOC)) can reduce diarrhea severity in patients receiving high-dose melphalan conditioning in preparation for auto-HCT in MM.Eligible patients undergoing first auto-HCT with melphalan conditioning (200mg/m2) for MM will be randomized in a 1:1 allocation to receive either prophylactic uproleselan plus SOC or placebo plus SOC.Shares up nearly 2% premarket.

For further details see:

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study